Filtered By:
Condition: Dementia
Management: Medicaid

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Prognostic factors for discharge destination after acute stroke: a comprehensive literature review.
Conclusion: Patient initial medical care, age and sex, neurological and medical complications and environmental/socio-economic factors should be considered in the decision-making process for discharge destination. [Box: see text]. PMID: 25250810 [PubMed - as supplied by publisher]
Source: Disability and Rehabilitation - September 24, 2014 Category: Rehabilitation Authors: Van der Cruyssen K, Vereeck L, Saeys W, Remmen R Tags: Disabil Rehabil Source Type: research

Prevalence of epilepsy/seizures as a comorbidity of neurologic disorders in nursing homes
Conclusions: The prevalence of epi/sz in the elderly nursing home population is >7-fold higher compared to community-dwelling elderly and is 7 to 30 times higher among those with certain comorbid neurologic conditions. Demographics and clinical characteristics had weaker associations with epi/sz prevalence.
Source: Neurology - February 19, 2017 Category: Neurology Authors: Birnbaum, A. K., Leppik, I. E., Svensden, K., Eberly, L. E. Tags: All Cerebrovascular disease/Stroke, All Cognitive Disorders/Dementia, Brain trauma, Prevalence studies, All Epilepsy/Seizures ARTICLE Source Type: research

As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research

FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval. “For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

2013 Alzheimer's disease facts and figures.
This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and society in general. It also explores the roles and unique challenges of long-distance caregivers, as well as interventions that target those challenges. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million comprise the older onset AD population. Throughout the coming decades, the baby boom ...
Source: The Journal of Alzheimers Association - March 20, 2013 Category: Psychiatry Tags: Alzheimers Dement Source Type: research

2013 Alzheimer's disease facts and figures
This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and society in general. It also explores the roles and unique challenges of long-distance caregivers, as well as interventions that target those challenges. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million comprise the older onset AD population. Throughout the coming decades, the baby boom ...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - March 1, 2013 Category: Geriatrics Authors: Alzheimer's Association Tags: Alzheimer's Association Report Source Type: research

2014 Alzheimer's disease facts and figures
This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. It also examines the impact of AD on women compared with men. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million are age 65 years or older. By mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to grow by about 9 million. Today, someone in the country d...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - March 1, 2014 Category: Geriatrics Authors: Alzheimer's Association Tags: Online Exclusives Source Type: research

Alzheimer's Association report.
This report discusses the public health impact of Alzheimer’s disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. It also examines the impact of AD on women compared with men. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million are age 65 years or older. By mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to grow by about 9 million. Today, someone in the country ...
Source: The Journal of Alzheimers Association - May 13, 2014 Category: Psychiatry Tags: Alzheimers Dement Source Type: research

2014 Alzheimer's disease facts and figures
This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. It also examines the impact of AD on women compared with men. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million are age 65 years or older. By mid-century, fueled in large part by the baby boom generation, the number of people living with AD in the United States is projected to grow by about 9 million. Today, someone in the country d...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - October 17, 2014 Category: Geriatrics Source Type: research

2013 Alzheimer's disease facts and figures
This report provides information to increase understanding of the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, health expenditures and costs of care, and effect on caregivers and society in general. It also explores the roles and unique challenges of long-distance caregivers, as well as interventions that target those challenges. An estimated 5.2 million Americans have AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD population; 5 million comprise the older onset AD population. Throughout the coming decades, the baby boom ...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - October 17, 2014 Category: Geriatrics Source Type: research

2015 Alzheimer's disease facts and figures
This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care and the overall effect on caregivers and society. It also examines the challenges encountered by health care providers when disclosing an AD diagnosis to patients and caregivers. An estimated 5.3 million Americans have AD; 5.1 million are age ≥65 years, and approximately 200,000 are age <65 years and have younger onset AD. By mid-century, the number of people living with AD in the United States is projected to grow by nearly 10 million, fueled in large part by the aging ba...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - March 24, 2015 Category: Geriatrics Source Type: research

2015 Alzheimer's disease facts and figures.
This report discusses the public health impact of Alzheimer’s disease (AD), including incidence and prevalence, mortality rates, costs of care and the overall effect on caregivers and society. It also examines the challenges encountered by health care providers when disclosing an AD diagnosis to patients and caregivers. An estimated 5.3 million Americans have AD; 5.1 million are age 65 years, and approximately 200,000 are age <65 years and have younger onset AD. By mid-century, the number of people living with AD in the United States is projected to grow by nearly 10 million, fueled in large part by the aging baby boo...
Source: The Journal of Alzheimers Association - May 21, 2015 Category: Psychiatry Tags: Alzheimers Dement Source Type: research

2016 Alzheimer's disease facts and figures
This report describes the public health impact of Alzheimer's disease, including incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers and society. It also examines in detail the financial impact of Alzheimer's on families, including annual costs to families and the difficult decisions families must often make to pay those costs. An estimated 5.4 million Americans have Alzheimer's disease. By mid-century, the number of people living with Alzheimer's disease in the United States is projected to grow to 13.8 million, fueled in large part by the aging baby boom generation. Today, someo...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - April 18, 2016 Category: Geriatrics Source Type: research

Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012 Epidemiology/Population
In conclusion, low adherence to antihypertensive medication has decreased among Medicare beneficiaries; however, rates of discontinuation and low adherence remain high.
Source: Hypertension - August 9, 2016 Category: Cardiology Authors: Tajeu, G. S., Kent, S. T., Kronish, I. M., Huang, L., Krousel-Wood, M., Bress, A. P., Shimbo, D., Muntner, P. Tags: Cardiovascular Disease, Epidemiology, Risk Factors, Hypertension Epidemiology/Population Source Type: research

2016 Alzheimer's disease facts and figures.
This report describes the public health impact of Alzheimer's disease, including incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers and society. It also examines in detail the financial impact of Alzheimer's on families, including annual costs to families and the difficult decisions families must often make to pay those costs. An estimated 5.4 million Americans have Alzheimer's disease. By mid-century, the number of people living with Alzheimer's disease in the United States is projected to grow to 13.8 million, fueled in large part by the aging baby boom generation. Today, someo...
Source: The Journal of Alzheimers Association - August 30, 2016 Category: Psychiatry Tags: Alzheimers Dement Source Type: research